{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-26-000016","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.987577+00:00","generated_at":"2026-05-15T21:35:07.644871+00:00","sec_items":["1.01","2.02","3.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aquestive posts Q4 net loss of $31.9M; Anaphylm resubmission delayed to Q3 2026","bullets":["Q4 revenue $13.0M (+10% YoY); net loss $31.9M ($0.26/share) incl $13.6M legal; excl legal net loss $18.7M.","Full year 2025 revenue $44.5M (down 23% YoY); net loss $83.8M ($0.78/share) incl $14.3M legal; cash $121.2M.","FY2026 guidance: revenue $46-50M, Non-GAAP adjusted EBITDA loss $35-30M, year-end cash target $70M.","RTW amendment extends Anaphylm deadline to June 30, 2027; warrant for 375k shares at $4; RTW commits $5M stock purchase.","Anaphylm CRL in Jan 2026; NDA resubmission planned Q3 2026 after Type A FDA meeting within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-26-000016","json":"https://secwatch.observer/filing/0001398733-26-000016.json","markdown":"https://secwatch.observer/filing/0001398733-26-000016.md","text":"https://secwatch.observer/filing/0001398733-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:35:07.644871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c79e4472d40b13a017aaebcf1cde9d894121bc2","claim":"Aquestive Therapeutics, Inc. entered into Share Purchase Commitment Agreement with certain RTW-affiliated funds valued at not less than $5,000,000 (effective 2026-03-03).","evidence_excerpt":"The Company also entered into a Share Purchase Commitment Agreement with certain RTW-affiliated funds, pursuant to which such funds committed to purchase, in the aggregate, not less than $5,000,000 of Common Stock during the 90-day period following the effective date of the agreement, at prices determined in accordance with Rule 415(a)(4) under the Securities Act.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain RTW-affiliated funds"},{"label":"Value","value":"not less than $5,000,000"},{"label":"Effective","value":"2026-03-03"}],"fact_type":"material_agreement"},{"claim_id":"bf0f71df644f43a43690081e5f795fb0af07ca73","claim":"Aquestive Therapeutics, Inc. entered into Warrant Issuance Agreement with funds managed by RTW (effective 2026-03-03).","evidence_excerpt":"Concurrently, the Company entered into a Warrant Issuance Agreement with funds managed by RTW pursuant to which the Company agreed to issue a warrant to purchase up to 375,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $4.00 per share, expiring on March 3, 2029.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"funds managed by RTW"},{"label":"Effective","value":"2026-03-03"}],"fact_type":"material_agreement"},{"claim_id":"f1238b7b2d2e015960cf25ce300beb2c211525b1","claim":"Aquestive Therapeutics, Inc. amended Amendment No. 1 to Purchase and Sale Agreement with funds managed by RTW Investments, LP (effective 2026-03-03).","evidence_excerpt":"On March 3, 2026, Aquestive Therapeutics, Inc. (the \"Company\") entered into Amendment No. 1 (the \"Amendment\") to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated August 13, 2025, with funds managed by RTW Investments, LP (\"RTW\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"funds managed by RTW Investments, LP"},{"label":"Effective","value":"2026-03-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}